Monte Rosa Therapeutics (GLUE) Enterprise Value (2023 - 2025)
Historic Enterprise Value for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$401.6 million.
- Monte Rosa Therapeutics' Enterprise Value fell 21983.04% to -$401.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$401.6 million, marking a year-over-year decrease of 21983.04%. This contributed to the annual value of -$381.0 million for FY2024, which is 6113.91% down from last year.
- As of Q3 2025, Monte Rosa Therapeutics' Enterprise Value stood at -$401.6 million, which was down 21983.04% from -$300.9 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Enterprise Value registered a high of -$47.0 million during Q2 2023, and its lowest value of -$401.6 million during Q3 2025.
- For the 3-year period, Monte Rosa Therapeutics' Enterprise Value averaged around -$195.3 million, with its median value being -$125.6 million (2024).
- Per our database at Business Quant, Monte Rosa Therapeutics' Enterprise Value tumbled by 6113.91% in 2024 and then crashed by 23591.41% in 2025.
- Over the past 3 years, Monte Rosa Therapeutics' Enterprise Value (Quarter) stood at -$236.4 million in 2023, then plummeted by 61.14% to -$381.0 million in 2024, then decreased by 5.42% to -$401.6 million in 2025.
- Its Enterprise Value was -$401.6 million in Q3 2025, compared to -$300.9 million in Q2 2025 and -$335.1 million in Q1 2025.